VP
Vanda Pharmaceuticals(VNDA)
WASHINGTON, DC
Pharmaceutical2 H-1B visas (FY2023)Focus: Small Molecules
Vanda Pharmaceuticals is a life sciences company focused on Small Molecules.
Neurology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (6)
BYSANTI
milsaperidone
Launch
ORAL · TABLET
2026
30
FANAPT
iloperidone
Peak
ORAL · TABLET
unknown. However, the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5-HT 2 ) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug.
schizophrenia
2009
0
HETLIOZ
tasimelteon
Peak
ORAL · CAPSULE
Melatonin Receptor Agonists
2014
0
HETLIOZ LQ
tasimelteon
Peak
ORAL · SUSPENSION
Melatonin Receptor Agonists
2020
0
NEREUS
tradipitant
Launch
ORAL · CAPSULE
2025
0
PONVORY
ponesimod
Peak
ORAL · TABLET
Sphingosine 1-Phosphate Receptor Modulators
2021
0
Pipeline & Clinical Trials
Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With
Smith Magenis SyndromeClinical Trials (1)
NCT02180451Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)
N/AData collection of sleep disturbances in individuals with SMS
Sleep Disturbances in Smith-Magenis SyndromeClinical Trials (1)
NCT03154697Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
N/AData collection on blindness and sleep problems
Sleep-wake Disorder in Blind IndividualsClinical Trials (1)
NCT01195558Patient Registry of Blind Subjects With Sleep-related Problems
N/AWGS Analysis of COVID-19 Positive Patients
Coronavirus InfectionClinical Trials (1)
NCT04353401WGS Analysis of COVID-19 Positive Patients
N/ATradipitant
GastroparesisClinical Trials (1)
NCT04474990Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis
N/ATransmeridian travel across multiple time zones
Jet Lag DisorderClinical Trials (1)
NCT02560103An Observational Study to Investigate the Effects of Rapid Transmeridian Travel
N/ATasimelteon Oral Capsule
HealthyClinical Trials (1)
NCT05572281Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers
Phase 1Tasimelteon
Renal ImpairmentClinical Trials (1)
NCT01526746Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function
Phase 1Tasimelteon
Healthy VolunteersClinical Trials (1)
NCT01540500Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine
Phase 1tasimelteon
HealthyClinical Trials (1)
NCT01637636Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.
Phase 1tasimelteon
Circadian Rhythm Sleep DisordersClinical Trials (1)
NCT02776215Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
Phase 1VLY-686
PruritusClinical Trials (1)
NCT01919944Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P
Phase 1tasimelteon
Hepatic ImpairmentClinical Trials (1)
NCT01271387Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
Phase 1tradipitant
Healthy VolunteersClinical Trials (1)
NCT02621385Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects
Phase 1Tasimelteon
Healthy VolunteersClinical Trials (1)
NCT06323655Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects
Phase 1VHX-896 and iloperidone
HealthyClinical Trials (1)
NCT04969211Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
Phase 1Iloperidone
Bipolar I DisorderClinical Trials (1)
NCT04127058Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
Phase 1tasimelteon
Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With EthanolClinical Trials (1)
NCT01578057Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol
Phase 1Iloperidone
SchizophreniaClinical Trials (1)
NCT04712734A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
Phase 1Trichostatin A
Relapsed or Refractory Hematologic MalignanciesClinical Trials (1)
NCT03838926Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Phase 1Tasimelteon
REM Behavior DisorderClinical Trials (1)
NCT05922995The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)
Phase 1VHX-896
HealthyClinical Trials (1)
NCT06803290Food Effect Study of VHX-896 in Healthy Volunteers
Phase 1Tasimelteon
Healthy VolunteersClinical Trials (1)
NCT01402076A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects
Phase 1Tasimelteon
Healthy VolunteersClinical Trials (1)
NCT01477619Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects
Phase 1VHX-896 and iloperidone
SchizophreniaClinical Trials (1)
NCT06494397Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Phase 1iloperidone
Safety and Tolerability of IloperidoneClinical Trials (1)
NCT01495169Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
Phase 1Iloperidone crystalline formulation
SchizophreniaTradipitant
Healthy VolunteerClinical Trials (1)
NCT04849559Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT07223632Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient
Phase 1/2VLY-686
GastroparesisClinical Trials (1)
NCT02970968Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
Phase 2Phase 2
Clinical Trials (1)
NCT00490945Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers
Phase 2Tasimelteon
Jet Lag DisorderClinical Trials (1)
NCT03291041A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
Phase 2VSJ-110
Dry EyeClinical Trials (1)
NCT07179055An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
Phase 2VSJ-110
Allergic ConjunctivitisClinical Trials (1)
NCT04622345Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
Phase 2Imsidolimab
Acne VulgarisClinical Trials (1)
NCT04856917A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Phase 2Imsidolimab
Generalized Pustular PsoriasisClinical Trials (1)
NCT03619902A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
Phase 2Tradipitant
Atopic DermatitisClinical Trials (1)
NCT02651714Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
Phase 2Clinical Trials (1)
NCT02004041Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
Phase 2Imsidolimab
Palmoplantar PustulosisClinical Trials (1)
NCT03633396A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Phase 2VSF-173
Excessive SomnolenceClinical Trials (1)
NCT00467441VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness
Phase 2Trichostatin A
Onychomycosis of ToenailClinical Trials (1)
NCT07065773Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
Phase 2Imsidolimab
Hidradenitis SuppurativaClinical Trials (1)
NCT04856930A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
Phase 2Imsidolimab
Acneiform EruptionsClinical Trials (1)
NCT04697069A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
Phase 2VQW-765
Performance AnxietyClinical Trials (1)
NCT04800237Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
Phase 2iloperidone
HypertensionClinical Trials (1)
NCT07090161Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Phase 2Tradipitant
Motion SicknessClinical Trials (1)
NCT03772340Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Phase 2Iloperidone
Parkinson Disease PsychosisClinical Trials (1)
NCT05344365A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Phase 2Imsidolimab
IchthyosisClinical Trials (1)
NCT04697056A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Phase 2Tradipitant
ObesityClinical Trials (1)
NCT06804603A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
Phase 2VSJ-110
Dry EyeClinical Trials (1)
NCT06296966A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 6 approved products, 82 clinical trials
Top TAs: Neurology, Immunology, Gastroenterology
H-1B (2023): 2 approvals
SEC Filings: 2 available
Portfolio Health
Launch2 (33%)
Peak4 (67%)
6 total products
Therapeutic Area Focus
Neurology
1 marketed11 pipeline
Immunology
1 marketed8 pipeline
Gastroenterology
5 pipeline
Psychiatry
3 marketed
Ophthalmology
2 pipeline
Dermatology
2 pipeline
Metabolic Diseases
2 pipeline
Infectious Diseases
1 pipeline
Marketed
Pipeline
Financials (FY2025)
Revenue
$193M24%
R&D Spend
$77M(40%)10%
Net Income
$3MCash
$102MVisa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub